Effects of demethylating agent 5-aza-2′-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines

被引:42
|
作者
Murakami, J
Asaumi, J
Maki, Y
Tsujigiwa, H
Kuroda, M
Nagai, N
Yanagi, Y
Inoue, T
Kawasaki, S
Tanaka, N
Matsubara, N
Kishi, K
机构
[1] Okayama Univ, Grad Sch, Grad Sch Med, Dept Oral & Maxillofacial Radiol, Okayama 7008525, Japan
[2] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Oral & Maxillofacial Radiol, Okayama 7008525, Japan
[3] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Oral Pathol, Okayama 7008525, Japan
[4] Okayama Univ, Grad Sch, Grad Sch Med, Dept Oral Pathol, Okayama 7008525, Japan
[5] Okayama Univ, Grad Sch, Grad Sch Med, Dept Radiol, Okayama 7008525, Japan
[6] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Radiol, Okayama 7008525, Japan
[7] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Oral Microbiol, Okayama 7008525, Japan
[8] Okayama Univ, Grad Sch, Grad Sch Med, Dept Oral Microbiol, Okayama 7008525, Japan
[9] Okayama Univ, Grad Sch, Grad Sch Med, Dept Radiol Technol, Okayama 7008525, Japan
[10] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Radiol Technol, Okayama 7008525, Japan
[11] Okayama Univ, Grad Sch, Grad Sch Dent, Dept Surg Oncol, Okayama 7008525, Japan
[12] Okayama Univ, Grad Sch, Grad Sch Med, Dept Surg Oncol, Okayama 7008525, Japan
关键词
maspin; methylation; 5-aza-2 '-deoxycytidine; FR901228;
D O I
10.1016/j.oraloncology.2003.12.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Maspin, which belongs to the serine protease inhibitor (serpin) superfamily, has been proposed as a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis. In the present study, we examined the effects of 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, and FR901228, a histone deacetylase (HDAC) inhibitor, on maspin expression in oral cancer cell tines. The expression levels of maspin mRNA were divided into two groups, which was the maspin tow-expressed and high-expressed cell lines in the 12 oral cancer cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines. Moreover, the methylation status was not altered after 5-aza-dC treatment. However, the transcription of the maspin gene was clearly increased following 5-aza-dC treatment in a number of oral cancer cell tines. These results imply that an action of 5-aza-dC is separate from induction of promoter demethylation. Treatment with FR901228 resulted in a time-dependent stimulation of the re-expression of maspin mRNA as early as 4 h after treatment in the maspin downregulated cells. The re-expression of the maspin gene may contribute to the recuperation of biological functions linked to FR901228 such as an inhibitory effect on tumor angiogenesis and cell invasion. These results indicate that maspin and its target genes may be excellent leads for future studies on the potential benefits of FR901228, a HDAC inhibitor, in cancer therapy. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 50 条
  • [1] Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
    Jun Murakami
    Jun-ichi Asaumi
    Noriko Kawai
    Hidetsugu Tsujigiwa
    Yoshinobu Yanagi
    Hitoshi Nagatsuka
    Tetsuyoshi Inoue
    Susumu Kokeguchi
    Shoji Kawasaki
    Masahiro Kuroda
    Noriaki Tanaka
    Nagahide Matsubara
    Kanji Kishi
    [J]. Cancer Chemotherapy and Pharmacology, 2005, 56 : 22 - 28
  • [2] Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
    Murakami, J
    Asaumi, J
    Kawai, N
    Tsujigiwa, H
    Yanagi, Y
    Nagatsuka, H
    Inoue, T
    Kokeguchi, S
    Kawasaki, S
    Kuroda, M
    Tanaka, N
    Matsubara, N
    Kishi, K
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 22 - 28
  • [3] Synergistic induction of cell death and apoptosis by the histone deacetylase inhibitor vorinostat and the demethylating agent 5-aza-2′-deoxycytidine in multiple myeloma
    Jost, Edgar
    Schubert, Claudia
    Brummendorf, Tim H.
    Galm, Oliver
    [J]. CANCER RESEARCH, 2010, 70
  • [4] Analysis of genes upregulated by the demethylating agent 5-aza-2′-deoxycytidine in gastric cancer cell lines
    Mikata, Rintaro
    Yokosuka, Osamu
    Fukai, Kenichi
    Imazeki, Fumio
    Arai, Makoto
    Tada, Motohisa
    Kurihara, Tomoko
    Zhang, Kaiyu
    Kanda, Tatsuo
    Saisho, Hiromitsu
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (07) : 1616 - 1622
  • [5] The histone deacetylase inhibitor FR901228 perferentially enhances adenovirus transgene expression in bladder cancer
    Okegawa, T
    Horie, S
    Nutahara, K
    Higashihara, E
    Hsieh, JT
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04): : 189 - 190
  • [6] Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines
    Tsurutani, J
    Soda, H
    Oka, M
    Suenaga, M
    Doi, S
    Nakamura, Y
    Nakatomi, K
    Shiozawa, K
    Yamada, Y
    Kamihira, S
    Kohno, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (02) : 238 - 242
  • [7] Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines
    Polakova, K.
    Bandzuchova, E.
    Kuba, D.
    Russ, G.
    [J]. LEUKEMIA RESEARCH, 2009, 33 (04) : 518 - 524
  • [8] Teratogenic effects of the demethylating agent 5-aza-2'-deoxycytidine in the Swiss Webster mouse
    Branch, S
    Francis, BM
    Brownie, CF
    Chernoff, N
    [J]. TOXICOLOGY, 1996, 112 (01) : 37 - 43
  • [9] Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-aza-2′-deoxycytidine
    Arai, Makoto
    Yokosuka, Osamu
    Hirasawa, Yuichi
    Fukai, Kenichi
    Chiba, Tetsuhiro
    Imazeki, Furnio
    Kanda, Tatsuo
    Yatomi, Mari
    Takiguchi, Yuichi
    Seki, Naohiko
    Saisho, Hiromitsu
    Ochiai, Takenori
    [J]. CANCER, 2006, 106 (11) : 2514 - 2525
  • [10] Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel
    Shang, Donghao
    Ito, Norlyuki
    Kamoto, Toshlyuki
    Ogawa, Osamu
    [J]. UROLOGY, 2007, 69 (05) : 1007 - 1012